Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient AffairsGlobeNewsWire • 05/20/21
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular EdemaGlobeNewsWire • 01/12/21